- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
European Pharma Launches Strategy Manifesto
Europe’s pharma industry association EFPIA has launched its ”Manifesto for an Integrated Life Sciences Strategy in Europe”.
Europe’s pharma industry association EFPIA has launched its ”Manifesto for an Integrated Life Sciences Strategy in Europe”.
The manifesto is built on three “separate but highly interdependent pillars”:
1. Improve health outcomes & remove inequalities to better patient benefits;
2. Support sustainable & predictable healthcare systems to speed access to medicines;
3. Build a thriving innovative life sciences sector to promote European competitiveness.
It follows the launch of EFPIA’s #HealthyEU Health and Growth campaign, which outlines opportunities and threats faced by the patients and the healthcare sector.
EFPIA President, Sanofi CEO Christopher Viehbacher, highlighted how the technological, behavioural and therapeutic innovations outlined in the Manifesto should be used to rebuild sustainable healthcare systems, improve access to medicines and “do a better job at preventing and treating chronic disease”.
The research-based pharmaceutical industry employs over 700,000 people in Europe, and contributes 17% of total business enterprise R&D employment.
To view the EFPIA Maifesto, click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
